HC Wainwright & Co. Maintains Absci (ABSI) Buy Recommendation
HC Wainwright & Co. has reiterated a Buy recommendation for Absci (ABSI) with a significant price target suggesting a 144.15% upside. The report highlights increased institutional ownership and a bullish put/call ratio, with key investors like ARK Investment Management increasing their stakes. Absci's projected annual revenue is expected to surge by 1,649.63% to $49MM.
ABSI Stock: HC Wainwright & Co. Raises Price Target to $8.00 | A
HC Wainwright & Co. has reiterated its Buy rating for Absci (ABSI) and increased the price target from $7.00 to $8.00, signaling confidence in the company's future performance. This updated target represents a 14.29% increase. Absci, an AI-powered synthetic biology company, receives an "Outperform" status from nine brokerage firms, with an average price target of $8.11, implying a significant upside from its current price.
Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatment, Analysts See Upside
Absci Corporation's ABS-201, an AI-designed antibody, has shown promising preclinical data for treating androgenetic alopecia by stimulating hair growth and preserving stem cells. Analysts from Needham and JonesTrading have reiterated Buy ratings, citing the drug's potential and strong market interest ahead of the planned HEADLINE study. The company's innovative approach targets a root cause of hair loss not addressed by current treatments, positioning ABS-201 for a significant market impact.
Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatment, Analysts See Upside
Absci Corporation's ABS-201, an AI-designed antibody, has shown promising preclinical data for treating androgenetic alopecia by stimulating hair growth and preserving stem cells. Analysts have reiterated Buy ratings, citing strong market interest and the drug's potential to offer a new approach to hair loss treatment. The company, a clinical-stage biopharmaceutical firm, is targeting a significant market of 80 million Americans affected by this condition.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $8
H.C. Wainwright analyst Swayampakula Ramakanth has reiterated a Buy rating for Absci Corp (ABSI.US) and increased the target price from $7 to $8. According to TipRanks, the analyst has a 43.4% success rate and an 18.4% average return over the past year. This revised target suggests continued confidence in Absci Corp's financial outlook.
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Absci Corporation, a clinical-stage biopharmaceutical company utilizing generative AI, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Absci management is scheduled to present on January 14, 2026, where they will discuss their Integrated Drug Creation™ platform and their pipeline of AI-designed therapeutics, including ABS-201™ for hair regrowth and endometriosis. A live and archived webcast of the presentation will be available on the company’s investor relations website.
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company utilizing generative AI for drug discovery, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Absci management is scheduled to present on Wednesday, January 14th at 3:45 p.m. Pacific Time. The company is advancing its Integrated Drug Creation platform to design innovative therapeutics, including its pipeline candidate ABS-201 for hair regrowth and endometriosis.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7
Needham analyst Gil Blum has reiterated a Buy rating for Absci Corp (ABSI.US) and maintained a target price of $7. Blum has a 39.8% success rate and a 7.7% average return over the past year, according to TipRanks data. The information presented is for informational purposes only and not investment advice.
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda has maintained a "Buy" rating for Absci Corp (ABSI.US). The analyst has a 58.1% success rate and an average return of 19.8% over the past year, according to TipRanks data. TipRanks provides independent analysis data on financial analysts, evaluating their recommendations based on success rates and average returns.
Absci (NASDAQ:ABSI) Receives "Buy" Rating from Needham & Company LLC
Needham & Company LLC has reaffirmed a "Buy" rating for Absci (NASDAQ:ABSI) and set a $7.00 price target, suggesting an 82.29% potential upside. Despite the positive rating, Absci reported disappointing quarterly results with a ($0.20) EPS miss and lower-than-expected revenue. Notably, director and CAO have recently purchased significant shares, indicating insider confidence in the AI biotech company.
Absci (NASDAQ: ABSI) posts ex vivo ABS-201 data on hair stem cells for AGA therapy
Absci (NASDAQ: ABSI) announced new human ex vivo data for its ABS-201 anti-PRLR antibody, demonstrating its potential to stimulate hair growth and regenerate the stem cell niche. These findings suggest ABS-201 could reverse follicle miniaturization by promoting vellus-to-terminal reconversion and neutralizing intrafollicular prolactin signaling for androgenetic alopecia (AGA) therapy. The full dataset was presented at a KOL seminar on December 11, 2025, and slides were made available on their investor relations website.
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
Absci Corporation announced new preclinical data for ABS-201, an AI-designed antibody for treating androgenetic alopecia (AGA), demonstrating its ability to stimulate hair growth and regenerate the stem cell niche in human ex vivo scalp models. The data indicate that ABS-201 prolongs the anagen phase, stimulates keratin synthesis, and protects the hair follicle progenitor cell pool, offering a novel disease-modifying mechanism for AGA. These findings will be presented at an ABS-201 Key Opinion Leader seminar, highlighting ABS-201's potential to reverse follicular miniaturization and drive vellus-to-terminal hair regeneration.
Absci (NASDAQ:ABSI) Transforms Biotechnology With AI Integration
Absci Corporation (NASDAQ:ABSI) is revolutionizing biologic drug discovery by integrating AI with laboratory technologies to streamline drug development and improve therapeutic accessibility. The company specializes in using artificial intelligence and synthetic biology to accelerate the discovery and production of biologic drugs. Absci collaborates with pharmaceutical companies to enhance the drug development process, from discovery to production.
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
Absci Corporation has announced a partnership with U.S. soccer legend Landon Donovan to raise awareness about the emotional impact of androgenetic alopecia (AGA) and the need for better therapeutic options. Donovan, who will share his personal hair loss journey at an upcoming Key Opinion Leader seminar, aims to destigmatize the condition and support Absci's scientific approach to developing treatments. Absci's investigational antibody, ABS-201, designed with generative AI, targets prolactin receptors for hair follicle regeneration and is expected to have interim data from its Phase 1/2a HEADLINE study in the second half of 2026.
Is Absci Poised for a Surge?
Absci Corporation (ABSI) has seen its stock rise by 9.52% following promising FDA designations and positive results from its Phase 1/2a HEADLINE study for ABS-201, targeting androgenetic alopecia. Despite revenue falling short of expectations, analysts maintain an overweight stance with slight price target adjustments, supported by strong cash reserves projected to last into 2028. The company's strategic pivot towards high-value treatment areas and leveraging AI initiatives are key factors for its potential trajectory amidst market volatility and upcoming clinical trial data.
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
Absci Corporation has partnered with U.S. soccer legend Landon Donovan to raise awareness about androgenetic alopecia (AGA) and the emotional impact of hair loss. Donovan will share his personal journey at Absci's upcoming KOL seminar, providing a patient perspective for the development of their investigational antibody, ABS-201, aimed at treating hair loss. This collaboration underscores Absci's commitment to patient-centered drug development for AGA, which affects millions and currently has limited effective treatments.
12 Health Care Stocks Moving In Tuesday's After-Market Session
This article details the performance of 12 health care stocks during Tuesday's after-market session, highlighting both gainers and losers. Stoke Therapeutics, Absci, BiomX, NewGenIvf Group, Curanex Pharmaceuticals, and Streamex saw their stock prices rise, while WORK Medical Tech Gr, Sana Biotechnology, Kazia Therapeutics, PDS Biotechnology, Denali Therapeutics, and Clearmind Medicine experienced declines. The report provides specific percentage changes and market capitalizations for each company mentioned.
Absci Corporation (NASDAQ:ABSI) Given Average Recommendation of "Moderate Buy" by Analysts
Absci Corporation (NASDAQ:ABSI) has received an average recommendation of "Moderate Buy" from seven analysts, with an average 12-month price target of $7.78. Recent insider transactions include significant share purchases by Director Menelas N. Pangalos and CAO Todd Bedrick, increasing insider ownership to 10.49%. Despite analyst optimism, Absci's latest quarterly results showed a miss on EPS and revenue, raising concerns about its financial performance.
Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine?
Absci (ABSI) recently initiated Phase 1/2a trials for ABS-201, an AI-designed drug for androgenetic alopecia, with interim data expected in late 2026. This marks a significant step in validating Absci's generative AI platform by translating its AI story into a clinical asset. While the milestone provides scientific validation, Absci faces challenges including minimal revenue, significant losses, dilution, and a short cash runway, necessitating careful investor consideration of its speculative valuation.
Absci doses first volunteers in phase 1/2a trial of hair loss antibody
Absci Corporation has initiated its Phase 1/2a HEADLINE study, dosing the first healthy volunteers with ABS-201, an investigational antibody for androgenetic alopecia. The biotech firm also plans to expand the trial's findings to address endometriosis, aiming for Phase 2 development in late 2026. The study will evaluate the safety and efficacy of ABS-201, a drug targeting the prolactin receptor, which has shown potential in treating both conditions.
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
Absci Corporation's stock jumped 13.4% after the company initiated dosing in a phase I/IIa study for its investigational candidate, ABS-201, targeting androgenetic alopecia (AGA). This novel anti-PRLR antibody, developed using Absci's generative AI platform, aims to evaluate the safety, tolerability, and efficacy of ABS-201, with interim data expected in the second half of 2026. The company also expanded its development strategy to include endometriosis as a second indication for ABS-201, leveraging data from the AGA study.
Absci Stock’s Financial Prospects: An In-Depth Analysis
Absci Corporation (NASDAQ: ABSI) is trading up amidst strategic refocusing on high-value medical needs like androgenetic alopecia and endometriosis. While the company posted a Q3 EPS that beat expectations, revenues were significantly below anticipated figures. Despite this, Absci has enough cash to support operations into mid-2028, and analysts maintain an 'Overweight' rating and a 'buy' recommendation, signaling cautious optimism for its long-term potential.
Absci Announces First Participants Dosed In Phase 1/2A Headline Trial
Absci (ABSI) announced that the first participants have been dosed in its Phase 1/2A HEADLINE™ Trial for ABS-201™, an AI-designed antibody targeting androgenetic alopecia. The company anticipates interim data in the second half of 2026 and plans for Phase 2 development of ABS-201 in endometriosis in Q4 2026.
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial
Absci (ABSI) recently dosed its first volunteers in a Phase 1/2a trial for ABS-201, an AI-designed antibody for androgenetic alopecia and endometriosis. Despite recent stock gains, the company's price-to-book ratio of 2.4x is relatively low compared to biotech peers. Investors are now evaluating whether Absci is an undervalued AI drug innovator or if its growth prospects are already priced in.
Absci (Nasdaq: ABSI) doses first volunteers in Phase 1/2a ABS-201 hair loss trial
Absci (Nasdaq: ABSI) has dosed the first healthy volunteers in its Phase 1/2a HEADLINE trial for ABS-201, an AI-designed anti-prolactin receptor antibody aimed at treating androgenetic alopecia (AGA). Interim data for AGA are expected in H2 2026, while the company also plans to initiate Phase 2 development for endometriosis in Q4 2026. The trial, designed to evaluate safety, tolerability, and efficacy, positions ABS-201 as a potential best-in-class treatment for these conditions.
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
Absci Corporation announced that the first healthy volunteers have been dosed in its Phase 1/2a HEADLINE study, evaluating ABS-201, an AI-designed antibody for androgenetic alopecia (AGA). The trial will assess the safety, tolerability, and efficacy of ABS-201, with interim data expected in the second half of 2026. Absci also plans to initiate Phase 2 clinical development for endometriosis in Q4 2026, leveraging synergistic development with the AGA study.
Absci to Participate in Upcoming Investor Conferences
Absci Corporation announced its participation in three upcoming investor conferences in November 2025: the Guggenheim Securities 2nd Annual Healthcare Innovation Conference, the UBS Global Healthcare Conference, and the Jefferies Global Healthcare Conference. The company will engage in fireside chats, presentations, and 1x1 meetings to discuss its advancements in breakthrough therapeutics using generative AI, including its Integrated Drug Creation™ platform and AI-designed pipeline.
Absci Corporation to Participate in Upcoming Investor Conferences in November 2025
Absci Corporation announced its participation in multiple investor conferences in November 2025, including the Guggenheim Securities 2nd Annual Healthcare Innovation Conference, UBS Global Healthcare Conference, and Jefferies Global Healthcare Conference. The clinical-stage biotech company plans to present and host investor meetings to discuss its generative AI-driven drug discovery platform and pipeline, which includes therapeutics for inflammatory bowel disease and hair regrowth. The article also details recent insider trading activity, hedge fund holdings changes, and analyst ratings for ABSI stock.
Absci (NASDAQ: ABSI) sets Nov. 12 webcast to discuss Q3 2025 results and business updates
Absci (NASDAQ: ABSI) announced it will report Q3 2025 financial and operating results and business updates after market close on Wednesday, November 12, 2025. The company will host a webcast and conference call at 4:30 p.m. ET (1:30 p.m. PT) on the same day to discuss the results and outlook. Live audio will be available on Absci's investor relations website, and an archived replay will be provided.
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
Absci announced it will report business updates and financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. The company will host a conference call and webcast to discuss the results and outlook at 4:30 p.m. Eastern Time. Absci is a clinical-stage biotech company focused on advancing breakthrough therapeutics using generative AI for drug discovery.
Absci (NASDAQ: ABSI) to join Guggenheim, UBS, Jefferies investor conferences Nov 10–18
Absci (NASDAQ: ABSI) announced its participation in three investor conferences in November 2025: the Guggenheim Securities 2nd Annual Healthcare Innovation Conference, the UBS Global Healthcare Conference, and the Jefferies Global Healthcare Conference. The company will engage in fireside chats, presentations, and 1x1 meetings with investors. Live and archived webcasts of the Guggenheim and Jefferies sessions will be accessible on Absci’s investor relations website.
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 69,894 Shares of Absci Corporation $ABSI
IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in Absci Corporation (NASDAQ:ABSI) by 79.1% during the second quarter, acquiring an additional 69,894 shares to bring its total to 158,298 shares valued at approximately $407,000. Analyst ratings for Absci are mixed, with a consensus target price of $7.98, and recent insider activity shows purchases by CAO Todd Bedrick and Director Menelas N. Pangalos. The company reported a quarterly loss and revenue below analyst estimates, but its Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company.
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
Absci (Nasdaq: ABSI) announced its plan to report business updates and financial and operating results for the third quarter 2025 after market close on Wednesday, November 12, 2025. A corresponding conference call will be webcast at 4:30 p.m. Eastern Time. The company is advancing an Integrated Drug Creation™ platform with AI models and a synthetic biology data engine, developing therapeutics like ABS-101 for inflammatory bowel disease and ABS-201 for hair regrowth.
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Absci Corporation (NASDAQ:ABSI) has received a consensus "Moderate Buy" rating from analysts, with an average one-year target price of $7.9780. The company recently reported earnings that missed analyst estimates and experienced insider stock acquisitions. Institutional investors and hedge funds have also adjusted their positions in ABSI.
Absci (NASDAQ:ABSI) Trading Down 2.6% – What’s Next? - Defense World
Absci (NASDAQ:ABSI) shares were down 2.6% on October 17, 2025. This article details recent analyst upgrades and downgrades, including reports from JPMorgan Chase & Co. and Morgan Stanley. It also covers the company's financial metrics, insider transactions, and institutional investor activity, highlighting major stake changes by firms like ARK Investment Management LLC and Massachusetts Financial Services Co. MA.
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
Absci will host a virtual seminar on December 11, 2025, focusing on its ABS-201 (anti-PRLR) program for androgenetic alopecia, featuring leading KOLs in dermatology and hair loss. The company also announced the accelerated initiation of the Phase 1/2a trial for ABS-201 in early December 2025, ahead of schedule, with an interim efficacy readout expected in the second half of 2026. ABS-201 represents a novel therapeutic approach targeting prolactin receptors to stimulate hair follicle regeneration, showing superior hair regrowth in preclinical studies compared to minoxidil.
Absci to accelerate hair loss drug trial, host webinar with experts - Investing.com Nigeria
This article indicates an application error on the Investing.com Nigeria website, preventing the display of content about Absci's hair loss drug trial. Consequently, no information regarding the trial acceleration or webinar details is available.
Absci climbs on clinical trial acceleration (ABSI:NASDAQ)
Absci (ABSI) shares surged approximately 18% after the AI-focused biotech announced an accelerated timeline for a proof-of-concept clinical trial. The trial is for ABS-201, an experimental therapy designed to treat androgenetic alopecia, an inherited form of hair loss. This positive development highlights the company's progress in its therapeutic pipeline.
Absci to accelerate hair loss drug trial, host webinar with experts By Investing.com - Investing.com South Africa
The provided article content indicates an application error when trying to load the main content from Investing.com South Africa. Therefore, the core information about Absci's hair loss drug trial acceleration and expert webinar is not available in the given text.
Phase 1/2a trial to start Dec 2025 — Absci hosts Dec 11 KOL seminar; interim efficacy readout H2 2026 - Stock Titan
Absci (NASDAQ: ABSI) is accelerating the initiation of its Phase 1/2a trial for ABS-201 (anti-PRLR) for androgenetic alopecia to early December 2025, ahead of previous guidance. The company will host a virtual seminar on December 11, 2025, featuring leading dermatology KOLs to discuss the program, with an interim efficacy readout anticipated in the second half of 2026. This development highlights Absci's progress in advancing its AI-designed therapeutic pipeline for hair regrowth.
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial - Yahoo Finance
Absci Corporation announced it will host a KOL seminar on December 11, 2025, focusing on its ABS-201 Androgenetic Alopecia program. The company also announced the acceleration of its Phase 1/2a trial for ABS-201, now expected to begin in early December 2025, ahead of its previous early 2026 guidance. The seminar will highlight the clinical trial path, differentiated profile, and market potential of ABS-201, with an interim efficacy readout anticipated in the second half of 2026.
Absci Corp. Experiences Evaluation Revision Amidst Mixed Performance Indicators and Market Dynamics - Markets Mojo
Absci Corp., a microcap company, has undergone an evaluation revision due to market fluctuations, with its stock currently priced at $3.66. While technical indicators show mixed trends with both bullish and bearish signals across different timeframes, the stock has significantly outperformed the S&P 500 in the past month and year-to-date, despite a decline in its one-year return. This revision highlights the company's volatile performance and its varying relationship to broader market trends.
Absci Stock Offers High-Risk AI Biotech Exposure With 110% Upside Forecast - Investing.com
This article focuses on Absci (NASDAQ: ABSI) stock, highlighting its potential for high growth in the AI biotech sector. It suggests a significant upside forecast of 110%, indicating a high-risk, high-reward investment opportunity. The article likely delves into the company's prospects and financial outlook.
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Absci, a clinical-stage biotech company, announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate AI-driven drug discovery. This partnership leverages OCI's AI infrastructure and AMD's hardware (Instinct™ MI355X GPUs and EPYC™ processors) to enhance the performance and scalability of Absci's generative AI Drug Creation Platform. The goal is to accelerate biologics design cycles, reduce costs, and bring novel therapeutics to patients more quickly.
Absci Strengthens Future: $64M Raise Powers AI Drug Pipeline as Almirall Partnership Grows
Absci Corporation (Nasdaq: ABSI) reported its Q2 2025 financial results and business updates, including a successful $64 million capital raise in July 2025, extending its operational runway into H1 2028. The company is advancing its clinical pipeline, with ABS-101 trials underway and ABS-201 targeting Phase 1/2a in early 2026. Absci also expanded its collaboration with Almirall for dermatological indications, potentially yielding up to $650 million in milestone payments.
Absci Announces Pricing of Public Offering of Common Stock
Absci Corporation announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at $3.00 per share, aiming to raise approximately $50 million. The company has also granted underwriters a 30-day option to purchase an additional 2,500,500 shares. Proceeds from the offering will be used to fund program advancement, platform investment, and general corporate purposes.
Absci and AMD Team Up to Revolutionize Drug Discovery with AI
Absci and AMD have announced a pivotal collaboration to revolutionize drug discovery using AI. AMD is investing $20 million in Absci, leveraging AMD Instinct™ accelerators and ROCm™ software to power Absci's AI-driven drug discovery processes and aiming to accelerate the creation of biologics through high-performance computing. This partnership is expected to reduce infrastructure costs, speed up innovation cycles, and enhance the performance of Absci's proprietary models, such as IgDesign1.
Absci Rings the Closing Bell
Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, will ring the Closing Bell at the Nasdaq MarketSite in Times Square. Sean McClain, Founder & CEO, will lead the ceremony on December 13, 2024, from 3:45 PM to 4:15 PM ET.
Absci Corporation Advances Internal Pipeline with New Drug Candidate ABS-201 for Androgenic Alopecia and Breakthroughs in AI-Designed Antibodies
Absci Corporation announced significant advancements in its drug development pipeline, including the selection of ABS-201 for androgenic alopecia, which showed superior hair regrowth in preclinical studies compared to minoxidil. The company also highlighted its AI platform's breakthrough in designing antibodies for a difficult HIV epitope. Absci detailed other pipeline candidates (ABS-101, ABS-301, ABS-501) and their expected clinical trial timelines, emphasizing its commitment to AI-driven drug discovery for unmet medical needs.
Absci CEO details Sloan Kettering Cancer Center partnership
Absci CEO Sean McClain discusses the company's partnership with Memorial Sloan Kettering Cancer Center. The collaboration aims to develop six new cancer therapeutics. The article provides a brief preview of this development.
